Literature DB >> 30972560

Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction.

Michelle L Hastings1, Timothy A Jones2.   

Abstract

Antisense oligonucleotides (ASOs) have shown potential as therapeutic molecules for the treatment of inner ear dysfunction. The peripheral sensory organs responsible for both hearing and equilibrium are housed within the inner ear. Hearing loss and vestibular balance problems affect a large portion of the population and limited treatment options exist. Targeting ASOs to the inner ear as a therapeutic strategy has unique pharmacokinetic and drug delivery opportunities and challenges. Here, we review ASO technology, delivery, disease targets, and other key considerations for development of this therapeutic approach.

Entities:  

Keywords:  RNA interference; Usher syndrome; antisense oligonucleotides; deafness; hearing loss; sensorineural hearing loss; splicing

Mesh:

Substances:

Year:  2019        PMID: 30972560      PMCID: PMC6554385          DOI: 10.1007/s13311-019-00729-0

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  90 in total

Review 1.  Morpholino antisense oligomers: the case for an RNase H-independent structural type.

Authors:  J Summerton
Journal:  Biochim Biophys Acta       Date:  1999-12-10

2.  Clinical aspects of round window membrane permeability under normal and pathological conditions.

Authors:  M V Goycoolea
Journal:  Acta Otolaryngol       Date:  2001-06       Impact factor: 1.494

Review 3.  Usher I syndrome: unravelling the mechanisms that underlie the cohesion of the growing hair bundle in inner ear sensory cells.

Authors:  Aziz El-Amraoui; Christine Petit
Journal:  J Cell Sci       Date:  2005-10-15       Impact factor: 5.285

4.  Spectrum of mutations in USH2A in British patients with Usher syndrome type II.

Authors:  B P Leroy; J A Aragon-Martin; M D Weston; D A Bessant; C Willis; A R Webster; A C Bird; W J Kimberling; A M Payne; S S Bhattacharya
Journal:  Exp Eye Res       Date:  2001-05       Impact factor: 3.467

Review 5.  Development of the ear and hearing.

Authors:  J W Hall
Journal:  J Perinatol       Date:  2000-12       Impact factor: 2.521

6.  Prevalence of 2314delG mutation in Spanish patients with Usher syndrome type II (USH2).

Authors:  M M Beneyto; J M Cuevas; J M Millán; C Espinós; E Mateu; P González-Cabo; M Baiget; M Doménech; S Bernal; C Ayuso; B García-Sandoval; M J Trujillo; S Borrego; G Antiñolo; M Carballo; C Nájera
Journal:  Ophthalmic Genet       Date:  2000-06       Impact factor: 1.803

7.  Dominant and recessive deafness caused by mutations of a novel gene, TMC1, required for cochlear hair-cell function.

Authors:  Kiyoto Kurima; Linda M Peters; Yandan Yang; Saima Riazuddin; Zubair M Ahmed; Sadaf Naz; Deidre Arnaud; Stacy Drury; Jianhong Mo; Tomoko Makishima; Manju Ghosh; P S N Menon; Dilip Deshmukh; Carole Oddoux; Harry Ostrer; Shaheen Khan; Sheikh Riazuddin; Prescott L Deininger; Lori L Hampton; Susan L Sullivan; James F Battey; Bronya J B Keats; Edward R Wilcox; Thomas B Friedman; Andrew J Griffith
Journal:  Nat Genet       Date:  2002-02-19       Impact factor: 38.330

8.  In vitro and in vivo suppression of GJB2 expression by RNA interference.

Authors:  Yukihide Maeda; Kunihiro Fukushima; Kazunori Nishizaki; Richard J H Smith
Journal:  Hum Mol Genet       Date:  2005-04-27       Impact factor: 6.150

Review 9.  Sensorineural hearing loss in children.

Authors:  Richard J H Smith; James F Bale; Karl R White
Journal:  Lancet       Date:  2005 Mar 5-11       Impact factor: 79.321

Review 10.  Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease.

Authors:  Jan Reiners; Kerstin Nagel-Wolfrum; Karin Jürgens; Tina Märker; Uwe Wolfrum
Journal:  Exp Eye Res       Date:  2006-03-20       Impact factor: 3.467

View more
  9 in total

Review 1.  Prenatal Somatic Cell Gene Therapies: Charting a Path Toward Clinical Applications (Proceedings of the CERSI-FDA Meeting).

Authors:  Akos Herzeg; Graça Almeida-Porada; R Alta Charo; Anna L David; Juan Gonzalez-Velez; Nalin Gupta; Larissa Lapteva; Billie Lianoglou; William Peranteau; Christopher Porada; Stephan J Sanders; Teresa N Sparks; David H Stitelman; Evi Struble; Charlotte J Sumner; Tippi C MacKenzie
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

Review 2.  Conversations in Cochlear Implantation: The Inner Ear Therapy of Today.

Authors:  Grant Rauterkus; Anne K Maxwell; Jacob B Kahane; Jennifer J Lentz; Moises A Arriaga
Journal:  Biomolecules       Date:  2022-04-29

3.  Nucleic Acid Therapeutics for Neurological Diseases.

Authors:  Jonathan K Watts; Robert H Brown; Anastasia Khvorova
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

Review 4.  Advances in genome editing for genetic hearing loss.

Authors:  Ning Ding; Sangsin Lee; Matan Lieber-Kotz; Jie Yang; Xue Gao
Journal:  Adv Drug Deliv Rev       Date:  2020-05-07       Impact factor: 15.470

Review 5.  Genetic insights, disease mechanisms, and biological therapeutics for Waardenburg syndrome.

Authors:  Sida Huang; Jian Song; Chufeng He; Xinzhang Cai; Kai Yuan; Lingyun Mei; Yong Feng
Journal:  Gene Ther       Date:  2021-02-25       Impact factor: 4.184

6.  Identification of Target Proteins Involved in Cochlear Hair Cell Progenitor Cytotoxicity following Gentamicin Exposure.

Authors:  Camron Davies; Rahul Mittal; Crystal Y Li; Hannah Marwede; Jenna Bergman; Nia Hilton; Jeenu Mittal; Sanjoy K Bhattacharya; Adrien A Eshraghi
Journal:  J Clin Med       Date:  2022-07-14       Impact factor: 4.964

Review 7.  Fetal gene therapy and pharmacotherapy to treat congenital hearing loss and vestibular dysfunction.

Authors:  Michelle L Hastings; John V Brigande
Journal:  Hear Res       Date:  2020-03-05       Impact factor: 3.208

Review 8.  Genetic Therapies for Hearing Loss: Accomplishments and Remaining Challenges.

Authors:  Shahar Taiber; Karen B Avraham
Journal:  Neurosci Lett       Date:  2019-10-03       Impact factor: 3.046

9.  Fetal antisense oligonucleotide therapy for congenital deafness and vestibular dysfunction.

Authors:  Lingyan Wang; J Beth Kempton; Han Jiang; Francine M Jodelka; Alev M Brigande; Rachel A Dumont; Frank Rigo; Jennifer J Lentz; Michelle L Hastings; John V Brigande
Journal:  Nucleic Acids Res       Date:  2020-05-21       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.